ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 1325 • ACR Convergence 2021

    Osteoporosis in Psoriatic Arthritis

    Sara M. Rojas Herrera1, Ignacio Braña Abascal1, Maria Priego Fernanddez-Martos1, Delia Fernandez Lozano1, Lara M. Chaves Chaparro1, Raul Veroz Gonzalez1, Juan J. Aznar Sanchez2 and Eugenio Chamizo Carmona1, 1Hospital de Mérida, Mérida, Spain, 2Hospital de Mérida, Merida, Spain

    Background/Purpose: Osteoporosis (OP) is a frequently underestimated comorbidity in immune-mediated inflammatory diseases (IMIDs). Its association with IMIDs is worse characterized in Psoriatic Arthritis (PsA) than…
  • Abstract Number: 0445 • ACR Convergence 2021

    Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis

    Jonathan Adachi1, Arkadi Chines2, Shuang Huang2, Kenneth Saag3, Willem Lems4 and Piet Geusens5, 1McMaster University/St. Joseph's Healthcare, Hamilton, ON, Canada, 2Amgen Inc., Thousand Oaks, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4VUmc, Amsterdam, Netherlands, 5Maastricht University, Genk, Belgium

    Background/Purpose: Denosumab (DMAb) is approved for the treatment of glucocorticoid (GC)–induced osteoporosis (GiOP). In a phase 3, international, active-controlled, double-blind, double-dummy study, treatment with DMAb…
  • Abstract Number: 0446 • ACR Convergence 2021

    Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies

    Jay Lin1, Carrie Nielson1, Mary Oates1, Cynthia Deignan2 and Zhigang Yu1, 1Amgen Inc., Thousand Oaks, CA, 2Amgen, Inc., Agoura Hills, CA

    Background/Purpose: This study is an ongoing USFDA post-marketing requirement (2020-2024) to assess the impact of boxed warning on romosozumab (romo) treatment and the feasibility of…
  • Abstract Number: 0447 • ACR Convergence 2021

    Bone Anabolic Effects of a Novel Orally-Available Small Molecule SIK2/SIK3 Inhibitor

    Cheng-Chia Tang1, Shiv Verma1, Steve De Vos2, David Amantini3, Philippe Clement-Lacroix3, Nicolas Desroy3, Antonio Speziale4, Daniel Brooks5, Mary Bouxsein5, Janaina da Silva Martins1, Yingshe Zhao6, Henry Kronenberg1 and Marc Wein1, 1MGH Endocrine Unit, Boston, MA, 2Galapagos NV, Mechelen, Belgium, 3Galapagos SASU, Romainville, France, 4Galapagos GmbH, Basel, Switzerland, 5Beth Israel Deaconess Medical Center, Boston, MA, 6MGH Endocrine Unnit, Boston, MA

    Background/Purpose: Orally-available bone anabolic agents represent a major unmet medical need for patients with osteoporosis. Widespread use of parathyroid hormone (PTH)-based osteo-anabolic therapies is limited…
  • Abstract Number: 0448 • ACR Convergence 2021

    Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as Predictor of Incident Fracture in Rheumatic Disease Patients on Long-term Glucocorticoid- a Five-year Longitudinal Study

    ho SO1, Xerox Lau1, Vivian Hung1, Steve Pang2, Shirley Ying3, Kitty Kwok4, Ka Lai Lee5, Jolly Lee6, Jack Lee1, James Griffith1, Ling Qin1 and Lai-Shan Tam7, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Kwong Wah Hospital, Hong Kong, Hong Kong, 3Prince Margaret Hospital, Hong Kong, Hong Kong, 4Queen Elizabeth Hospital, Hong Kong, Hong Kong, 5Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, 6Tai Po Hospital, Hong Kong, Hong Kong, 7Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)

    Background/Purpose: Impaired bone quality and strength estimated by high resolution peripheral quantitative computer tomography (HR-pQCT) in patients with rheumatic diseases on long-term glucocorticoid (LTGC) therapy…
  • Abstract Number: 0653 • ACR Convergence 2021

    Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center

    Padmini Parameswaran1 and Michael Lucke2, 1Allegheny Health Network Medical Education Consortium, Pittsburgh, PA, 2Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Since the first description of polymyalgia rheumatica (PMR) in the early 1950s, the ideal dose and duration of glucocorticoid therapy has varied. In 2015,…
  • Abstract Number: 1135 • ACR Convergence 2021

    Osteoporosis Assessment and Outcomes in Candidates for Liver Transplantation in a Tertiary Center

    Cristina Rodríguez-Alvear1, MARIANO ANDRES1, Maria-Luisa Peral-Garrido2, Irene Calabuig3, Ernesto Tovar-Sugrañes1, Mari-Carmen López-González1, Pilar Bernabeu1, Agustín Martínez-Sanchis1, Ximo Esteve1, Paloma Vela1, Cayetano Miralles1 and Maria Vega Jovani Casano4, 1Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, 2Hospital General Universitario de Alicante-ISABIAL, Novelda, Spain, 3Hospital General Universitario de Alicante, Alicante, Spain, 4National Health system, Alicante, Spain

    Background/Purpose: A rapid loss of bone mass and an increase in fractures have been described in the first six months after liver transplantation. This phenomenon…
  • Abstract Number: 1137 • ACR Convergence 2021

    REMS Technology for the Assessment of Bone Health in a Male Population

    Delia Ciardo1, Paola Pisani1, Fiorella Anna Lombardi1, Marco Di Paola1, Roberto Franchini1, Maurizio Muratore2, Francesco Conversano1 and Sergio Casciaro1, 1National Research Council, Institute of Clinical Physiology, Lecce, Italy, Lecce, Italy, 2Vito Fazzi Hospital, ASL-LE, O.U. of Rheumatology, Lecce, Italy, Lecce, Italy

    Background/Purpose: This study aimed to evaluate the diagnostic accuracy of the ultrasound-based densitometric technology called Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis…
  • Abstract Number: 1138 • ACR Convergence 2021

    Assessing Trends in Dual Energy X-Ray Absorptiometry (DXA) Utilization Among Medical Providers in the United States

    Timothy Edgil1, Kenneth Saag2, Jeffrey Curtis3 and Maria I. Danila2, 1Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The twenty first century has seen falling reimbursement rates for dual energy X-ray absorptiometry (DXA) testing coupled with a rising elderly population in the…
  • Abstract Number: 1139 • ACR Convergence 2021

    Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements

    Muntarin Karim1, lorien ahn2, Jordan Thompson1, Christina Downey3, Lorena Salto4 and Karina Torralba5, 1Loma Linda University, Redlands, CA, 2loma linda university medical center, Loma Linda, CA, 3Loma Linda University Medical Center, Redlands, CA, 4Loma Linda University Health, Loma Linda, CA, 5Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA

    Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
  • Abstract Number: 1140 • ACR Convergence 2021

    Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?

    Alexandra Chop1, Rajesh Kupuraju1, Ruchi Patel1, Kristen Salava1, Madhuri Duggirala1, Aparna Baburaj1, Andrea Berger2, Jason Brown1 and David Bulbin3, 1Geisinger Medical Center, Danville, PA, 2Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, 3Geisinger Health System, Danville, PA

    Background/Purpose: Glucocorticoids are commonly prescribed for a multitude of indications, yet have many side effects, one of which is glucocorticoid induced osteoporosis (GIOP). The 2017…
  • Abstract Number: 1141 • ACR Convergence 2021

    Factors Associated with Fragility Fracture in Patients with Systemic Mastocytosis: Data from an Inception Cohort in a Single Centre

    Karen Carpio Astudillo1, Filip Skrabski2, ISABEL CASTREJON3, Jose Maria Alvaro-Gracia2, Alicia Garcia Prieto2 and Teresa González4, 1Hospital General Universitario Gregorio Maraon, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Pfizer Spain, Chicago, 4H Gregorio Maraon, Madrid, Spain

    Background/Purpose: Systemic Mastocytosis (SM) is a very rare disease (0,5 -1 per 10000 in adults). Most common manifestations are skin related or anaphylaxis, however almost…
  • Abstract Number: 1143 • ACR Convergence 2021

    Predictors of Engagement in Bone Health Care Among Rural Veterans at Risk for Osteoporosis

    Karla Miller1, Kimberly McCoy2, Christopher Richards2, Aaron Seaman3 and Samantha Solimeo4, 1Department of Internal Medicine, Rheumatology Section, Veterans Affairs Salt Lake City Health Care System; Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, 2VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation, Department of Veterans Affairs, CADRE, Iowa City VA HCS, Iowa City, IA, 3VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City (VRHRC-IC); Division of Genera l Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, 4VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation; and Primary Care Analytics Team Iowa City (PCAT-IC), Department of Veterans Affairs, CADRE, Iowa City VA HCS Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA

    Background/Purpose: A virtual bone health team (BHT) model was implemented to identify, screen, and treat rural Veterans at risk for osteoporosis. This study was conducted…
  • Abstract Number: 1145 • ACR Convergence 2021

    Prevalence of and Risk Factors for Vertebral Fractures and Low Bone Mass Density Among Women Aging with HIV in Peru

    Diego Cabrera1, Mijahil P. Cornejo2, Rebecca Slotkin3, Yvett Pinedo4, Wei Yu5, Wenmin Guan5, Patricia J. Garcia6 and Evelyn Hsieh7, 1Yale School of Medicine, Lima, Peru, 2Grunenthal peruana, Lima, Peru, 3Yale New Haven Hospital, New Haven, CT, 4Hospital Nacional Arzobispo Loayza, Lima, Peru, 5Department of Radiology, Chinese Academy of Medicine Sciences and Peking Union Medical College Hospital, Beijing, China (People's Republic), 6Universidad Peruana Cayetano Heredia, Lima, Peru, 7Yale School of Medicine, New Haven, CT

    Background/Purpose: Few studies in Latin America and the Caribbean have evaluated osteoporosis and fracture epidemiology among populations at increased risk for secondary osteoporosis, such as…
  • Abstract Number: 0117 • ACR Convergence 2020

    Development of an In Vitro Trabecular Human Bone Model to Recapitulate Features of Glucocorticoid-induced Osteoporosis

    Annemarie Lang1, Karoline Diesing1, Alexandra Damerau1, Moritz Pfeiffenberger1, Timo Gaber1 and Frank Buttgereit2, 1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, 2Charité University Medicine, Berlin, Germany

    Background/Purpose: The bone matrix consists of inorganic and organic components and a variety of specialized cells such as osteoblasts, osteocytes and osteoclasts. The bone-forming osteoblasts…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology